Parataxis Korea Terminates Option Contract for Idiopathic Pulmonary Fibrosis Treatment Candidate, a Strategic Decision
Parataxis Korea terminated the option contract for the technology introduction of a candidate treatment for idiopathic pulmonary fibrosis with Cellion BioMed. This decision was made as a strategic move to enhance competitiveness in its bio business division.
No further milestone or royalty payments are required, and the previously received 1 billion KRW technology fee will not be returned.
This termination does not involve any capital changes or shareholder return measures, and is not expected to directly impact financial soundness indicators.
[AI Summary]Parataxis Korea strategically terminated a potential future cash outflow through the option contract, alleviating financial burden, but the pipeline reduction may raise concerns about long-term growth drivers. The stock price impact is likely limited in the short term, but market assessment of the bio business direction is warranted.
KOSDAQ Filing Information
Major Management Matters Related to Investment Decision (Termination of Technology Introduction Option Contract for Idiopathic Pulmonary Fibrosis and Other Fibrosis Treatment Candidates Termination of Technology Introduction Option Contract for Idiopathic Pulmonary Fibrosis and Other Fibrosis Treatment Candidates)